Zobrazeno 1 - 10
of 88
pro vyhledávání: '"Li Chun Lu"'
Autor:
Tsung-Hao Liu, San-Chi Chen, Kun-Ming Rau, Li-Chun Lu, Po-Ting Lin, Yung-Yeh Su, Wei Teng, Shiue-Wei Lai, Ren-Hua Yeh, Tsui-Mai Kao, Pei-Chang Lee, Chi-Jung Wu, Chien-Hung Chen, Chih-Hung Hsu, Shi-Ming Lin, Yi-Hsiang Huang, Li-Tzong Chen, Ann-Lii Cheng, Ying-Chun Shen
Publikováno v:
Liver Cancer (2024)
Introduction The progression patterns, dispositions, and outcomes of patients with advanced hepatocellular carcinoma (HCC) who achieved durable responses with immunotherapy remain poorly characterized. Methods Patients with advanced HCC who received
Externí odkaz:
https://doaj.org/article/982567d91e37462383001cc9dc3d4719
Publikováno v:
Cellular and Molecular Gastroenterology and Hepatology, Vol 15, Iss 6, Pp 1351-1369 (2023)
Background & Aims: Complex communications between hepatocytes and Kupffer cells (KCs) are known to drive or suppress hepatocarcinogenesis, with controversial data in the literature. In previous experiments that aimed to decipher hepatocyte/KC interac
Externí odkaz:
https://doaj.org/article/fbf22ff817e64ceaaa6b4a6e3a01135f
Publikováno v:
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-5 (2021)
Abstract We reported a patient with unresectable hepatocellular carcinoma (HCC) who initially received 15 cycles of atezolizumab plus bevacizumab combination and had best tumor response of partial response, but later experienced disease progression.
Externí odkaz:
https://doaj.org/article/af190b21f4104e7c8c39ab7566577cb5
Publikováno v:
Journal of Cancer Research & Practice. Apr-Jun2023, Vol. 10 Issue 2, p45-49. 5p.
Autor:
Shih-Hung Yang, Li-Chun Lu, Hsiang-Fong Kao, Bang-Bin Chen, Ting-Chun Kuo, Sung-Hsin Kuo, Yu-Wen Tien, Li-Yuan Bai, Ann-Lii Cheng, Kun-Huei Yeh
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
Immune checkpoint inhibitors have limited efficacy in the treatment of pancreatic ductal adenocarcinoma (PDAC). We investigated prognostic markers for nivolumab-based therapy in advanced or recurrent PDAC. Consecutive patients receiving nivolumab-bas
Externí odkaz:
https://doaj.org/article/749d5b4821494be3beefc00082360660
Autor:
Ching-Tso Chen, Yin-Hsun Feng, Chia-Jui Yen, San-Chi Chen, Yun-Tzu Lin, Li-Chun Lu, Chih-Hung Hsu, Ann-Lii Cheng, Yu-Yun Shao
Publikováno v:
Hepatology International. 16:1199-1207
The combination of atezolizumab and bevacizumab (Atezo-Bev) has become the standard first-line therapy for patients with advanced hepatocellular carcinoma (HCC), but the prognosis and treatment pattern after its treatment failure are unclear.We revie
Publikováno v:
Annual Review of Cancer Biology; 2024, Vol. 8 Issue 1, p15-33, 19p
Publikováno v:
Journal of Cancer Research and Practice, Vol 3, Iss 1, Pp 14-18 (2016)
Perivascular epithelioid cell tumor (PEComa) is a rare subtype of soft tissue sarcoma that coexpresses melanocytic and smooth muscle markers. We report a case of malignant PEComa arising from the gastrointestinal tract. Definitive diagnosis of malign
Externí odkaz:
https://doaj.org/article/f37a26d505a64f9d8676f3b829e58566
Autor:
Li-Chun Lu, Cecilia Deantonio, Cintia C. Palu, Yi-Hsuan Lee, Laura S. Mitchell, Marianne Cowan, Matthew Corser, Lorcan Sherry, Ann-Lii Cheng, Sonia Quaratino, Yu-Yun Shao, Richard C.A. Sainson, Chih-Hung Hsu
Publikováno v:
Oncology. 100:419-428
Introduction: Inducible co-stimulator (ICOS), an important co-stimulatory receptor on effector T cells (Teffs), may also contribute to tumor growth due to its high expression on regulatory T cells (Tregs). This study explored the clinical significanc
Publikováno v:
Experimental Hematology & Oncology, Vol 10, Iss 1, Pp 1-5 (2021)
Experimental Hematology & Oncology
Experimental Hematology & Oncology
We reported a patient with unresectable hepatocellular carcinoma (HCC) who initially received 15 cycles of atezolizumab plus bevacizumab combination and had best tumor response of partial response, but later experienced disease progression. After sub